ICU Girisim Sermayesi Yatirim Ortakligi A.S. (ICUGS.IS)
- Previous Close
10.93 - Open
10.93 - Bid 10.83 x --
- Ask 10.83 x --
- Day's Range
10.74 - 10.96 - 52 Week Range
10.38 - 33.12 - Volume
3,899,718 - Avg. Volume
12,360,221 - Market Cap (intraday)
751.99M - Beta (5Y Monthly) 0.34
- PE Ratio (TTM)
10.82 - EPS (TTM)
1.00 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Rhea Venture Capital Investment Trust Inc is a venture capital investment trust specializing in seed/startup, early, mid venture, middle market, buyouts, PIPEs investments in small and medium enterprises. The fund seeks to invest in healthcare including all areas except hospital services (medical equipment, pharma, distribution, logistics, consumables, IT, laboratories, insurance, and payment systems); telecom, technology including IT, software, hardware, media, internet; infrastructure including energy, waste management, logistics, clean technology; and business services including finance, hospitality, and education. It prefers to invest in Turkey. The fund typically invests between $1 million and $10 million in companies with sales between $5 million and $20 million and EBITDA between $0.75 million and $3 million. It prefers to take a majority stake. However, the fund can also selectively invest with a minority stake. It seeks to hold financial and board level control in its portfolio companies. The fund seeks to exit its investments in five years either through a block sale or an IPO.
www.rheagirisim.com/en13
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: ICUGS.IS
View MorePerformance Overview: ICUGS.IS
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is BIST 100 (XU100.IS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ICUGS.IS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ICUGS.IS
View MoreValuation Measures
Market Cap
751.99M
Enterprise Value
676.77M
Trailing P/E
10.79
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.90
Price/Book (mrq)
1.36
Enterprise Value/Revenue
2.61
Enterprise Value/EBITDA
8.98
Financial Highlights
Profitability and Income Statement
Profit Margin
26.91%
Return on Assets (ttm)
17.85%
Return on Equity (ttm)
22.50%
Revenue (ttm)
259.14M
Net Income Avi to Common (ttm)
69.73M
Diluted EPS (ttm)
1.00
Balance Sheet and Cash Flow
Total Cash (mrq)
116.31M
Total Debt/Equity (mrq)
7.43%
Levered Free Cash Flow (ttm)
-43.74M